Exploring the role of GADD45A in Alzheimer's disease
Exploring the role of GADD45A in Alzheimer's disease
批准号:
10373344
负责人:
Andrew P Escayg
金额:
$41.61万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-02-01 至 2024-01-31
关键词:
3xTg-AD mouseATAC-seqAffectAlzheimer&aposs DiseaseAlzheimer&aposs disease brainAlzheimer&aposs disease modelAlzheimer&aposs disease patientAmericanBehaviorBinding ProteinsBiologicalBrainCellsChromatinClinicalCognitionCognitiveCognitive deficitsDNADNA MethylationDataData SetDementiaDioxygenasesEconomic BurdenEpigenetic ProcessEpilepsyExhibitsFamilyGADD45A geneGene ExpressionGenesGenetic TranscriptionGlutamate ReceptorGoalsHealthcare SystemsHippocampus (Brain)Impaired cognitionImpairmentIntensive CareInterventionKnockout MiceLearningLinkLong-Term PotentiationMediatingMemoryMemory LossMessenger RNAModificationMolecularMusMutant Strains MiceN-MethylaspartateNerve DegenerationNeurodegenerative DisordersNeuronsOxidesPathogenesisPathologicPathway interactionsPatientsPharmacologyPhenotypePlayProteinsRNA BindingRegulationReversal LearningRiskRoleSynapsesSynaptic plasticityTestingTherapeuticTranscriptTranslatingUp-RegulationWild Type Mousebaseclinically relevantcomorbidityeffective therapyefficacious treatmentepigenetic regulationexcitatory neuronfamily burdengene repressiongenome-widegenomic locusimprovedlong term memorymemory consolidationmouse modelmutantnervous system disorderneurodevelopmentoverexpressionpreventrecruitsynaptic functiontranscriptome sequencing
中文摘要
项目总结
英文摘要
PROJECT SUMMARY
Alzheimer’s disease (AD) is a severe form of dementia that affects over 5 million Americans, making it one of
the most common neurodegenerative disorders. Patients with AD exhibit a severe form of progressive memory
loss that cannot be prevented with current pharmacological interventions, and are at increased risk of developing
comorbid neurological disorders such as epilepsy. The lack of efficacious treatments and the intensive care
required for late-stage AD patients also places a significant economic burden on families and the American
healthcare system: an estimated ~$200 billion annually. Recent studies have demonstrated a link between
epigenetic modifications and AD. One epigenetic modification of particular relevance is 5-hydroxymethylcytosine
(5hmC) which is highly enriched in neurons and is dynamically regulated during neurodevelopment. Alterations
in 5hmC have been observed in the brains of patients with AD and in mouse AD models, raising the possibility
that aberrant DNA 5hmC might contribute to AD pathogenesis. GADD45A mediates the establishment of 5hmC
in cells and also possesses RNA binding activity. Interestingly, Gadd45a-/- null mice exhibit decreased
hippocampal long-term potentiation (LTP) and impaired long-term memory and reversal learning, whereas
overexpression of Gadd45a in pyramidal excitatory neurons of wild-type mice enhances LTP and memory
consolidation. In addition, our preliminary data and publicly available RNA-seq data sets indicate that GADD45A
is downregulated in neurons isolated from AD patients. Gadd45a expression and 5hmC levels are also reduced
in several mouse models of AD (including the 3xTG AD model to be used in this proposal). Based on these
observations, we hypothesize that GADD45A plays an important role in neuronal function and cognition
through epigenetic regulation of 5hmC levels and subsequent modulation of gene expression in
neurons. We will test this hypothesis in Aim 1 by comparing 5hmC levels and distribution between Gadd45a-/-
null mutants and WT littermates. We will also perform RNA-seq and ATAC-seq on these mice to functionally
relate observed changes in 5hmC with specific alterations in gene expression and chromatin accessibility. Given
that overexpression of Gadd45a enhances LTP and memory consolidation, we hypothesize that
upregulation of GADD45A will be therapeutic in AD. Therefore, in Aim 2, we will examine whether
overexpression of Gadd45a in the 3xTG mouse model of AD can ameliorate deficits in synaptic activity, improve
learning and memory, and reduce spontaneous epileptiform discharges. These phenotypes were selected
because they represent important pathological features of AD and are mechanistically related since cognitive
decline in the AD brain is believed to be accelerated by neuronal hyperexcitability.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SCN8A encephalopathy: disease mechanisms and treatment
-
批准号:10586642
-
项目类别:
-
资助金额:$55.38万
-
财政年份:2023
-
负责人:Andrew P Escayg
-
依托单位:
Exploring the role of oxytocin in the regulation of neuronal excitability
-
批准号:10593062
-
项目类别:
-
资助金额:$47.29万
-
财政年份:2021
-
负责人:Andrew P Escayg
-
依托单位:
Exploring the role of oxytocin in the regulation of neuronal excitability
-
批准号:10397642
-
项目类别:
-
资助金额:$47.42万
-
财政年份:2021
-
负责人:Andrew P Escayg
-
依托单位:
Exploring the range of seizure and behavioral phenotypes due to SCN8A mutations
-
批准号:9978424
-
项目类别:
-
资助金额:$15.07万
-
财政年份:2020
-
负责人:Andrew P Escayg
-
依托单位:
Exploring reversible AChE inhibitors as a treatment for refractory epilepsies
-
批准号:9764633
-
项目类别:
-
资助金额:$42.54万
-
财政年份:2019
-
负责人:Andrew P Escayg
-
依托单位:
N-terminal huntingtin and Huntington disease neuropathology
-
批准号:10117290
-
项目类别:
-
资助金额:$44.84万
-
财政年份:2017
-
负责人:Andrew P Escayg
-
依托单位:
Towards the development of an effective treatment for SCN1A-derived epilepsy
-
批准号:9195849
-
项目类别:
-
资助金额:$23.26万
-
财政年份:2016
-
负责人:Andrew P Escayg
-
依托单位:
Towards the development of an effective treatment for SCN1A-derived epilepsy
-
批准号:9272959
-
项目类别:
-
资助金额:$19.35万
-
财政年份:2016
-
负责人:Andrew P Escayg
-
依托单位:
A novel target for the treatment of temporal lobe epilepsy
-
批准号:9087344
-
项目类别:
-
资助金额:$46.58万
-
财政年份:2015
-
负责人:Andrew P Escayg
-
依托单位:
SCN1A dysfunction and neuropsychiatric comorbidities
-
批准号:8702781
-
项目类别:
-
资助金额:$23.3万
-
财政年份:2014
-
负责人:Andrew P Escayg
-
依托单位:
Understanding the role of sodium channels in epilepsy
-
批准号:8185742
-
项目类别:
-
资助金额:$34.25万
-
财政年份:2011
-
负责人:Andrew P Escayg
-
依托单位:
Understanding the role of sodium channels in epilepsy
-
批准号:8492182
-
项目类别:
-
资助金额:$31.54万
-
财政年份:2011
-
负责人:Andrew P Escayg
-
依托单位:
Understanding the role of sodium channels in epilepsy
-
批准号:8291970
-
项目类别:
-
资助金额:$32.79万
-
财政年份:2011
-
负责人:Andrew P Escayg
-
依托单位:
A mouse model of human idiopathic generalized epilepsy
-
批准号:8030277
-
项目类别:
-
资助金额:$7.65万
-
财政年份:2010
-
负责人:Andrew P Escayg
-
依托单位:
A mouse model of human idiopathic generalized epilepsy
-
批准号:8139081
-
项目类别:
-
资助金额:$7.49万
-
财政年份:2010
-
负责人:Andrew P Escayg
-
依托单位:
Towards the development of a novel treatment for epilepsy
-
批准号:7897877
-
项目类别:
-
资助金额:$19.38万
-
财政年份:2009
-
负责人:Andrew P Escayg
-
依托单位:
Scn8a and Seizure Resistance
-
批准号:8241100
-
项目类别:
-
资助金额:$31.57万
-
财政年份:2009
-
负责人:Andrew P Escayg
-
依托单位:
Scn8a and Seizure Resistance
-
批准号:8044874
-
项目类别:
-
资助金额:$31.75万
-
财政年份:2009
-
负责人:Andrew P Escayg
-
依托单位:
Scn8a and Seizure Resistance
-
批准号:7634390
-
项目类别:
-
资助金额:$33.84万
-
财政年份:2009
-
负责人:Andrew P Escayg
-
依托单位:
SODIUM CHANNEL REGULATION AND DISEASE
-
批准号:7046789
-
项目类别:
-
资助金额:$27.64万
-
财政年份:2005
-
负责人:Andrew P Escayg
-
依托单位:
国内基金
海外基金
登录
查看更多内容
基于ATAC-seq与DNA甲基化测序探究染色质可及性对莲两生态型地下茎适应性分化的作用机制
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:
-
依托单位:
利用ATAC-seq联合RNA-seq分析TOP2A介导的HCC肿瘤细胞迁移侵
袭的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:柳静
-
依托单位:
面向图神经网络ATAC-seq模体识别的最小间隔单细胞聚类研究
-
批准号:62302218
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2023
-
负责人:张双全
-
依托单位:
基于ATAC-seq策略挖掘穿心莲基因组中调控穿心莲内酯合成的增强子
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:黄铭坤
-
依托单位:
基于单细胞ATAC-seq技术的C4光合调控分子机制研究
-
批准号:32100438
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:涂晓雨
-
依托单位:
基于ATAC-seq技术研究交叉反应物质197调控TFEB介导的自噬抑制子宫内膜异位症侵袭的分子机制
-
批准号:82001520
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:汤小晗
-
依托单位:
靶向治疗动态调控肺癌细胞DNA可接近性的ATAC-seq分析
-
批准号:81802809
-
项目类别:青年科学基金项目
-
资助金额:21.0万元
-
批准年份:2018
-
负责人:蔡梅春
-
依托单位:
运用ATAC-seq技术分析染色质可接近性对犏牛初级精母细胞基因表达的调控作用
-
批准号:31802046
-
项目类别:青年科学基金项目
-
资助金额:27.0万元
-
批准年份:2018
-
负责人:张龚炜
-
依托单位:
基于ATAC-seq和RNA-seq研究CWIN调控采后番茄果实耐冷性作用机制
-
批准号:31801915
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2018
-
负责人:茹磊
-
依托单位:
基于ATAC-seq高精度预测染色质相互作用的新方法和基于增强现实的3D基因组数据可视化
-
批准号:31871331
-
项目类别:面上项目
-
资助金额:59.0万元
-
批准年份:2018
-
负责人:张治华
-
依托单位: